U.S. Markets closed

Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition

Allison DeAngelis
Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition

Cambridge-based Epizyme is now awaiting FDA for approval for its epigenetics first product, tazemetostat, with plans to quickly expand its applications.